... .by injection aimed at treating “diabetic macular edema, a condition that can cause blurred vision and blindness.”
Reuters (9/26) reports that during the treatment physicians insert a small cylindrical tube with medicine on the back of the eye, the spot where diabetic macular edema usually forms.
For the more technical minded:
ILUVIEN is an injectable, non-erodible, intravitreal implant for the treatment of DME, a potentially blinding condition that affects approximately one million people in the U.S. alone. ILUVIEN is designed to release the drug fluocinolone acetonide (FA) for up to three years. Importantly, the device is small enough to be injected into the back of the eye with a 25 gauge needle creating a self-sealing hole. This insertion procedure is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.
DME is a common complication of diabetic retinopathy and is caused by fluid build-up in the central vision portion of the retina. Retinal blood vessels in a diabetic's eyes deteriorate and leak, causing retinal swelling.